Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
about
Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.Smart, programmable and responsive injectable hydrogels for controlled release of cargo osteoporosis drugs.Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massReactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells.Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis.Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique.
P2860
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Once-yearly zoledronic acid in ...... tures in postmenopausal women.
@en
Once-yearly zoledronic acid in ...... tures in postmenopausal women.
@nl
type
label
Once-yearly zoledronic acid in ...... tures in postmenopausal women.
@en
Once-yearly zoledronic acid in ...... tures in postmenopausal women.
@nl
prefLabel
Once-yearly zoledronic acid in ...... tures in postmenopausal women.
@en
Once-yearly zoledronic acid in ...... tures in postmenopausal women.
@nl
P2093
P2860
P921
P356
P1476
Once-yearly zoledronic acid in ...... tures in postmenopausal women.
@en
P2093
Dimitra Papadimitriou
Fotini Galapi
K Papadias
Sophia Vlachou
P2860
P304
P356
10.2147/CIA.S2046
P407
P577
2008-01-01T00:00:00Z